STRUCTURAL INTERVENTIONS

AMPLATZER™ AMULET™ LAA OCCLUDER

Designed to treat patients with non-valvular atrial fibrillation (AF) who are at risk of ischemic stroke, the Amplatzer™ Amulet™ LAA Occluder offers complete closure of the left atrial appendage (LAA) and immediately eliminates the need for oral anticoagulants.1

AMPLATZER™
AMULET™ LAA OCCLUDER

As a stroke prevention device for patients with nonvalvular atrial fibrillation, the Amplatzer™ Amulet™ Left Atrial Appendage (LAA) Occluder is part of the industry-leading Amplatzer line of structural intervention occluders. The Amplatzer Amulet LAA occluder is a part of Abbott’s broad structural heart portfolio.

Percutaneous, catheter-based occlusion of the LAA—the therapy provided by the Amplatzer Amulet LAA Occluder—is an increasingly performed procedure aiming to reduce the risk of stroke in patients with nonvalvular atrial fibrillation.1 Current evidence suggests that transcatheter occlusion of the LAA reduces the risk of thromboembolic complications associated with nonvalvular atrial fibrillation.2,3

Reducing Stroke Risk

David Hildick-Smith, MD, Royal Sussex County Hospital, Brighton, England

“What this therapy [use of the Amplatzer Amulet LAA Occluder] does for the patient is twofold. One, it physically deals with the problem and reduces the risk of stroke very substantially. But more than that, it also offers patients a peace of mind.”

Animation video:
Amplatzer™ Amulet™ LAA Occluder

DUAL SEAL TECHNOLOGY TO COMPLETELY SEAL THE ORIFICE

Innovative dual seal design, leverages a proven Amplatzer design that has been trusted for over 20 years.1

First: Amplatzer Amulet Occluder conforms to different shapes of LAA anatomy and requires minimal depth for implant.

Second: DISC completely covers the LAA opening - effectively sealing blood flow around the device.

The first and only LAA Occluder for AF patients and cases like these

Life-long medication to reduce stroke risk is not an option for many patients and many reasons. The Amplatzer™ Amulet™ LAA Occluder permanently closes this primary stroke pathway without requiring these patients to endure the challenges of Oral Anticoagulants (OACs).
 

  • Comorbidities and concerns about drug interactions

    OACs are incompatible with treatments for many comorbidities including depression or arthritis. Amplatzer Amulet occluder is an alternative to oral anticoagulants that can increase the risk of drug interactions.

    Michael (AGE 75)

    Michael has Non-Valvular Atrial Fibrillation (NVAF) and a CHA2DS2-VASc score of 5. He is reducing his stroke risk without increasing his risk for drug interactions.

    NVAF patients with comorbidities should know that there is an alternative.

  • Adherence or compliance issues

    Adverse effects, the cost of Novel Oral Anticoagulants (NOACs), or the monitoring required when taking warfarin, often make compliance a challenge for patients. Amplatzer Amulet occluder is an alternative to life-long oral anticoagulants that can lead to noncompliance.

    Sarah (AGE 73)

    Sarah has NVAF and a CHA2DS2-VASc score of 4. She is reducing her stroke risk without having to take OACs for the rest of her life.

    NVAF patients who struggle with compliance should know that there is an alternative.
     

  • Daily activities that increase bleeding risk

    The long-term bleeding risks associated with OACs such as warfarin are particularly concerning for patients with active lifestyles or occupations. Consider Amplatzer Amulet occluder for active patients.

    Rita (AGE 65)

    Rita has NVAF and a CHA2DS2-VASc score of 4. She is reducing her stroke risk without having to limit her travel and play with her grandchildren. 

    NVAF patients who want to remain active should know that there is an alternative.

  • A history of falls and a high risk of bleeding

    A fall can erode a patient’s confidence and willingness to engage in everyday tasks. It can also lead to a major bleeding event. Consider Amplatzer Amulet occluder when you or your patients are concerned about the risk of falls or bleeding.

    Nathan (AGE 80)

    Nathan, who has NVAF and a CHA2DS2-VASc score of 5, hit his head the last time he fell. He and his doctor want to reduce his stroke risk without increasing his risk for a major bleeding event.

    NVAF patients at high risk for bleeding should know that there is an alternative.
     

  • A contraindication to OACs

    For patients with poorly controlled or uncontrolled hypertension, oral anticoagulants are contraindicated. Amplatzer Amulet occluder is an alternative to life-long oral anticoagulants that are not a safe choice for these patients.

    Regina (AGE 55)

    Regina, who has NVAF and a CHA2DS2-VASc score is 4, has had poorly controlled hypertension for 10 years. Her doctor wants to reduce her stroke risk without jeopardizing her safety.

    NVAF patients with poorly controlled hypertension should know that there is an alternative.

For educational purposes only; not real patient cases.

Confidence with Amplatzer Amulet treatment

Derek, Worthing, England

“The confidence it gave me, knowing that they didn’t have to thin the blood down, and the chance of having a blood clot was diminished by over 90%. It was just mind blowing. I felt I’ve won the lottery.”

Beneficial outcomes for both patient and physician

The first and only LAA occluder that ensures the best fit across the most diverse range of LAA anatomies2

The Amplatzer™ line pioneered the technology of structural heart occlusion devices and remains the leading choice for implanters worldwide. Amplatzer devices, and other life-changing innovations from Abbott, continue to transform futures.

130+

DISCOVERING NEW WAYS TO MAKE LIFE BETTER FOR MORE THAN 130 YEARS4

160+

MAKING A DIFFERENCE
IN OVER 160 COUNTRIES4

109K

EMPLOYEES WORKING AROUND THE WORLD TO MAKE A LASTING IMPACT ON HEALTH4

CLINICAL DATA


See the latest clinical data for the Amplatzer Amulet LAA Occluder
 

see clinical data

NEW VERSION AVAILABLE
GET THE AMPLATZER PORTFOLIO APP

The Amplatzer Portfolio App helps physicians determine which Amplatzer Structural Interventions device to use by suggesting applicable devices based on respective Instructions for Use.

MAT-2008374 v2.0 | Item approved for Global OUS use only.

Copyright © 2022 Abbott, 3200 Lakeside Dr, Santa Clara, 95054, U.S.A.
Caution: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at eifu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.
Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.
Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

MAT-2000631 v10.0 | Item approved for OUS use only.

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

YOU ARE ABOUT TO LEAVE
www.structural­heart.abbott

You are now leaving www.structuralheart.abbott. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.